Business, energy, technology, markets and global industry news from Business News Today

pembrolizumab

PharmaDeviceNews pembrolizumab
Kelun-Biotech’s sacituzumab tirumotecan plus pembrolizumab met the Phase III PFS endpoint in first-line PD-L1-negative non-squamous NSCLC. Representative image.
Pharma & Biotech

Why Kelun-Biotech’s latest sac-TMT Phase III result could matter more than the headline suggests

Kelun-Biotech reports improved Phase III PFS with sac-TMT plus pembrolizumab, while survival and detailed safety data remain pending.

Read More
FDA approval of Keytruda and Keytruda Qlex with Padcev expands perioperative treatment options for adults with muscle-invasive bladder cancer. Representative image.
Pharma & Biotech

Can Keytruda plus Padcev replace cisplatin chemotherapy before bladder cancer surgery?

FDA approval moves Keytruda and Padcev into perioperative MIBC regardless of cisplatin eligibility, intensifying the contest for standard care.

Read More
FDA approval of Padcev plus Keytruda expands perioperative treatment options for adults with muscle-invasive bladder cancer regardless of cisplatin eligibility. Representative image.
Pharma & Biotech

Pfizer and Astellas secure wider FDA label for Padcev plus Keytruda in muscle-invasive bladder cancer

FDA expands Padcev plus Keytruda to adults with muscle-invasive bladder cancer regardless of cisplatin eligibility, reshaping perioperative care.

Read More
Representative image: Samsung Bioepis’ SB27 Keytruda biosimilar trial results highlight a potentially important step toward lower-cost pembrolizumab competition in the global oncology market.
Pharma & Biotech

Samsung Bioepis SB27 meets Phase 3 endpoint as Keytruda biosimilar competition accelerates

Read how Samsung Bioepis SB27’s positive Phase 1 and Phase 3 data could reshape the Keytruda biosimilar race and oncology access.

Read More
Pharma & Biotech

Merck and Gilead secure FDA approval for a new ADC-immunotherapy backbone in advanced TNBC

The new regimen replaces conventional chemotherapy with a Trop-2-directed antibody-drug conjugate while retaining PD-1 blockade, offering longer disease control but leaving overall survival, sequencing and cost questions unresolved.

Read More
Representative image: An oncology specialist reviews lung scans and clinical trial data as Pfizer’s sigvotatug vedotin Phase 3 survival miss shifts attention to second-line patients, biomarker strategy and first-line combinations.
Pharma & Biotech

Sigvotatug vedotin Phase 3 miss tests Pfizer’s case for integrin beta-6 targeted ADCs

Discover why Pfizer’s sigvotatug vedotin Phase 3 miss shifts attention to second-line patients, biomarkers and first-line combinations.

Read More
Representative image of a clinician reviewing kidney cancer scans, reflecting Merck & Co., Inc.’s FDA approval of Keytruda and Welireg combinations for adjuvant clear cell renal cell carcinoma treatment.
Pharma & Biotech

Merck moves Welireg earlier as FDA clears Keytruda combinations in high-risk ccRCC

Find out how Merck’s Keytruda and Welireg approval could reshape adjuvant clear cell renal cell carcinoma treatment.

Read More
Representative image of a modern pathology laboratory where automated PD-L1 cancer diagnostic testing is supporting faster immuno-oncology treatment decisions, reflecting Agilent Technologies’ expanded FDA approval for PD-L1 IHC 22C3 pharmDx on the Dako Omnis platform.
Medical Devices & Diagnostics

Agilent wins FDA backing to move more Keytruda-linked PD-L1 testing onto Dako Omnis

Find out how Agilent’s expanded PD-L1 test approval could change automated cancer diagnostics and oncology lab workflows.

Read More
Representative image of a lung cancer treatment setting, as OptiTROP-Lung05 data put sacituzumab tirumotecan at the centre of the first-line NSCLC immunotherapy debate.
Pharma & Biotech

Can TROP2 ADCs reshape first-line NSCLC after Kelun-Biotech’s OptiTROP-Lung05 win?

A TROP2 ADC just pushed past pembrolizumab alone in first-line lung cancer. See why OptiTROP-Lung05 matters now.

Read More
Representative image: A clinician reviews bladder cancer imaging in a modern oncology setting, reflecting Merck’s KEYTRUDA plus Padcev EU regulatory milestone for cisplatin-ineligible muscle-invasive bladder cancer patients.
Pharma & Biotech

Why Merck’s CHMP win for KEYTRUDA plus Padcev matters in muscle-invasive bladder cancer

Merck’s bladder cancer push is moving earlier in Europe. KEYTRUDA plus Padcev could reset cisplatin-ineligible MIBC care.

Read More